Idox has provided a trading update for the year ended 31 October 2024. Management expects to report full-year results in line with market expectations. Idox has delivered strong (c.20%) revenue growth and good adjusted EBITDA growth in the year, alongside healthy cash generation. Order growth of 9% is encouraging as it demonstrates both the underlying quality and strength, and the positive outlook. We look forward to the FY24 results to see how FY25 has started and how the growth story will continue.